CompletedNot Applicable

HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION

France210 participantsStarted 2013-02

Plain-language summary

HYPID-2 study is an extension of HYPID study (NCT01443598) : HYPID-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization. It concerns only incident patients (i.e patients included within 6 months after PH diagnosis) whereas HYPID concerned prevalent and incident cases. The primary aim is the same than HYPID : identify prognostic factors

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients newly diagnosed with: * Pre capillary pulmonary hypertension at right heart sided catheterization with: mPAP \> or = 25 mmHg, PCWP \< or = 15 mmHg * Interstitial lung disease with diffuse infiltrative opacities on chest CT scan Exclusion Criteria: * Pulmonary hypertension related to a thromboembolic disease * Respiratory disease other than diffuse interstitial lung disease * Any etiological factor of pulmonary arterial hypertension based on NICE 2013 classification other than diffuse interstitial lung disease * Any progressive disease associated to a life expectancy less than 6 months other than pulmonary hypertension, diffuse interstitial lung disease and respiratory insufficiency

What they're measuring

Overall survival

Timeframe: 2 years

Trial details

NCT IDNCT02799771

SponsorGroupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-02

View on ClinicalTrials.gov More Pulmonary Arterial Hypertension trials